Location: United States, California, Newark
Total raised: $47M
Founded date: 2009
Investors 2
| Date | Name | Website |
| - | Asset Mana... | assetman.c... |
| - | Sofinnova ... | sofinnova.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.11.2018 | Series B | $42M | - |
| 28.04.2015 | Series A | $5M | - |
Mentions in press and media 17
| Date | Title | Description |
| 04.10.2022 | InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth | SAN FRANCISCO, CA – October 4, 2022 – InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing inhaled therapies for cardiovascular diseases, today announced the appointment of Robert Lisicki as chief ex... |
| 23.10.2020 | InCarda Therapeutics Raises $30M in Series C | SAN FRANCISCO, CA, InCarda Therapeutics has raised $30 million through the first close of a Series C equity financing. >> Click here for more funding data on InCarda Therapeutics >> To export InCarda Therapeutics funding dat... |
| 21.10.2020 | InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing | Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for Presentation at American Heart Association S... |
| 21.10.2020 | InCarda raises $30M to reimagine afib treatment with drug-device combo | Flecainide has been around to treat atrial fibrillation since the '80s, but Grace Colón, CEO of InCarda Therapeutics, thinks it needs a face-lift. Armed with $30 million in venture funding, InCarda hopes to make the drug available as an at-... |
| 08.11.2019 | InCarda Therapeutics raises $35 million | InCarda Therapeutics — which is developing an inhaled paroxysmal atrial fibrillation drug — filed an SEC Form D confirming the sale of more than $35 million in equity. The Newark, Calif.–based drug-device combo company sold nearly $35.3 mil... |
| 09.11.2018 | InCarda Therapeutics raises $42M in Series B for inhaled cardiovascular drug | The company plans to use the funding mainly for a Phase II study it recently initiated of InRhythm (flecainide), for recent-onset paroxysmal atrial fibrillation, or PAF. InRhythm’s active ingredient is a generic drug ordinarily administered... |
| 07.11.2018 | InCarda Completes $42M Oversubscribed Series B Financing | - |
| 28.04.2015 | InCarda Therapeutics Raises over $5M in Series A Financing | InCarda Therapeutics, Inc., a San Francisco, CA-based biotechnology company focused on the development and commercialization of therapies for acute cardiovascular conditions via the inhalation route, raised over $5m Series A financing. Pote... |
| 28.04.2015 | InCarda Therapeutics Inks Over $5M Series A | SAN FRANCISCO, CA, Privately-held biotechnology company has raised over $5 million with potential tranches totaling an additional $1.5 million. >> Click here for more funding data on InCarda Therapeutics >> To export InCarda... |
| - | InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020 | Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) P... |
Show more